Drug profile · INN
milsaperidone
BYSANTI
milsaperidone (BYSANTI) is an FDA-listed pharmaceutical active ingredient. Associated with Vanda Pharmaceuticals Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.
Drug details — milsaperidone
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 2
- Data quality
- 0.89
Quick answer
milsaperidone (BYSANTI) is an FDA-listed pharmaceutical active ingredient. Associated with Vanda Pharmaceuticals Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
-
US 12427132
Method of improving sleep
granted -
US 12419869
Methods of treating multiple sclerosis
granted -
US 12403134
Method for improving or enhancing cognition
granted -
US 12357616
Methods of treating multiple sclerosis
granted -
US 11845990
Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
granted -
US 11458116
Method of improving sleep
granted -
US 11433057
Method for improving or enhancing cognition
granted -
US 11060144
Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
granted -
US 10570453
Method of predicting a predisposition to QT prolongation
granted -
US 10570452
Method of predicting a predisposition to QT prolongation
granted -
US 10563259
Method of treatment based on polymorphisms of the KCNQ1 gene
granted -
US 10563260
Method of predicting a predisposition to QT prolongation
granted -
US 10563261
Method of predicting a predisposition to QT prolongation
granted -
US 10272075
Method and composition for treating an alpha adrenoceptor-mediated condition
granted -
US 9987264
Method and composition for treating a serotonin receptor-mediated condition
granted -
US 9708291
Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone
granted -
US 9446038
Method and composition for treating a serotonin receptor-mediated condition
granted -
US 9157121
Method of treatment based on polymorphisms of the KCNQ1 gene
granted -
US 9072742
Method of predicting a predisposition to QT prolongation
granted -
US 9074256
Method of predicting a predisposition to QT prolongation
granted
Frequently asked questions
What is milsaperidone?
milsaperidone (BYSANTI) is an FDA-listed pharmaceutical active ingredient. Associated with Vanda Pharmaceuticals Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for milsaperidone?
BYSANTI is a marketed brand name for milsaperidone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of milsaperidone?
milsaperidone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.